Monika Alcobev IPO subscribed 1.32x on Day 2 so far; Check GMP, and other details
About the Company
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
The BSE SME IPO of Monika Alcobev, a luxury alcohol importer and distributor, has seen moderate investor response, with the issue subscribed 1.32 times as of 11:01 AM on July 17. The public offering, which opened on July 16, will close on July 18.As per the latest update, investors placed bids for 55.21 lakh shares, exceeding the 41.80 lakh shares on offer. The non-institutional investor (NII) segment has shown the strongest interest, with 2.79 times subscription for their reserved quota of 12.24 lakh shares. Meanwhile, retail investors have subscribed to 50% of their allocation (18.81 lakh shares), and qualified institutional buyers (QIBs) have subscribed 1.09 times their share.In the grey market—an unofficial trading venue for IPO shares ahead of listing—Monika Alcobev was seen quoting Rs 10 premium over the issue price. Based on the upper end of the IPO price band at Rs 286, this translates to a potential listing gain of around 3.5%, assuming current market sentiment holds.Monika Alcobev aims to raise Rs 165.63 crore through a combination of fresh issue and offer for sale (OFS) in its IPO. The company's shares are expected to debut on the BSE SME platform on July 23.With just one day left for bidding, investor traction in the retail and QIB segments will be critical in determining final subscription levels and listing-day sentiment. Monika Alcobev IPO comprises a fresh issue of 47.91 lakh shares worth Rs 137.03 crore, and OFS of 10 lakh shares aggregating Rs 28.60 crore by existing shareholders.The price band is set at Rs 271–286 per share, and investors can bid in lots of 400 shares, translating to a minimum investment of Rs 2.16 lakh for retail applicants. So far, there is no visible grey market premium (GMP) for the issue, indicating muted pre-listing excitement among informal investors.Monika Alcobev has already raised Rs 46.06 crore from anchor investors, including institutional players, on July 15.MUFG Intime India is the registrar, while Marwadi Chandarana Intermediaries is the lead manager for this BSE SME offer. Bhansali Value Creations is the market maker for the issue.Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. is serving as the book-running lead manager for the Monika Alcobev IPO, with MUFG Intime India Private Limited (Link Intime) appointed as the registrar for the issue.Founded in 2015, Monika Alcobev is a prominent importer and distributor of premium and luxury alcoholic beverages in India and neighbouring markets. Its portfolio features over 70 international brands, including names like Jose Cuervo, Bushmills, and Onegin Vodka.The company operates across India, Sri Lanka, Nepal, the Maldives, and Bangladesh, serving hotels, restaurants, retail outlets, and airport duty-free segments. It boasts a wide distribution network and employs 191 people as of March 2025.Monika Alcobev reported a 25% jump in revenue and a 39% rise in net profit in FY25, with EBITDA growing to Rs 46.19 crore.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
25 minutes ago
- Business Standard
Schaeffler India Q1FY26 results: Net profit increases 14% to ₹294 crore
The company had posted a standalone PAT of Rs 253.96 crore in the year-ago quarter, according to a regulatory filing Press Trust of India Mumbai Auto parts maker Schaeffler India on Friday reported a 14 per cent rise in standalone profit after tax (PAT) to Rs 294.44 crore in the June 2025 quarter. The company had posted a standalone PAT of Rs 253.96 crore in the year-ago quarter, according to a regulatory filing. Schaeffler India follows a January-December financial year. Its revenue from operations (net) for the quarter under review rose to Rs 2,282.16 crore from Rs 2,071.93 crore in the April-June period of 2024, it stated. "We have a year-on-year higher revenue across all businesses and continue to sustain our trajectory of registering double-digit growth for the fifth consecutive quarter. Quality of earnings continued to improve given efficiency measures and concentrated efforts on our strategic priority of localisation," its Managing Director and Chief Executive Officer Harsha Kadam said. This performance, coupled with improved financial and operating metrics, resulted in a good first half of 2025, he added.
&w=3840&q=100)
Business Standard
25 minutes ago
- Business Standard
Cipla Q1 net profit up 10%, driven by consumer health and generics
Pharma major Cipla posted a 10 per cent year-on-year increase in its consolidated net profit, reaching Rs 1,297 crore in the first quarter of financial year 2026 (Q1FY26), up from Rs 1,177 crore. Revenue from operations also rose by 3.2 per cent YoY, reaching Rs 6,837 crore compared to Rs 6,672 crore last year. The increase in profit and revenue was attributed to robust performance in the consumer healthcare and generic markets. Sequentially, revenue was up by 3.6 per cent, with net profit increasing by 6.2 per cent. The results were announced during market hours. Cipla's stock rose by 2.95 per cent, ending the day's trade at Rs 1,531.10 on the BSE. Umang Vohra, Managing Director and Global Chief Executive Officer of Cipla, stated, 'I am pleased to share that we continue to make considerable progress across our focused markets. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipelines, and focusing on resolving regulatory challenges.' For FY26, Cipla has guided for EBITDA margins between 23.5 per cent and 24.5 per cent. Growth will be driven by respiratory product launches in the US, new rollouts in India and emerging markets, and strong momentum in the GLP-1 segment, which is seen as a transformative opportunity. While US revenue forecasts remain conservative due to expected Lenalidomide erosion, the company is confident that its expanding pipeline will offset the impact. This quarter, Cipla's India business reported strong performance across all segments. In branded prescription, key therapies like respiratory, urology, cardiac, anti-diabetes, and anti-infectives outpaced market growth, with the chronic portfolio forming 61.5 per cent of sales. Trade generics saw robust growth, aided by strong execution, new product introductions (including entry into orthopaedics), and tech-led initiatives, with seven product launches during the quarter. In consumer health, anchor brands Nicotex, Omnigel, and Cipladine retained leadership in their categories. In North America, Cipla posted revenue of $226 million, driven by differentiated assets. Albuterol reached 19.5 per cent market share, while Lanreotide reached 21 per cent. Launches like nano paclitaxel vials and Nilotinib capsules are set to boost Cipla's oncology and complex generics presence. A strategic tie-up will also bring its first U.S. biosimilar to market in Q2 FY26. For Africa, the company delivered an 11 per cent YoY growth in USD terms, with private market growth. Cipla ranked number 3 overall in South Africa's private market, with its prescription business at number 2, driven by growth in key therapies, tender business, and new launches. In the emerging markets and Europe, the company's focused strategy yielded 8 per cent growth in USD terms, supported by momentum in both DTM and B2B segments, while maintaining stable margins. Cipla also reported a relatively higher research and development (R&D) spend this quarter at 6.2 per cent of revenue. The company sees its biggest growth opportunity in executing a strong pipeline of new product launches, particularly in the respiratory segment, with 3–4 launches lined up for the US and several more planned for emerging markets and India. Cipla is also continuing to actively invest in biosimilars and mRNA platforms, with a Centre of Excellence in Europe, capacity building at its Goa facility, and collaboration with Ethris. A biosimilar in supportive therapy is on track for launch in FY26. The company is also advancing early-stage work in CAR-T and cell/gene therapies, with ongoing evaluations and potential partnerships. Cipla holds a strong net cash position of Rs 10,800 crore and maintains a cautious, science-led M&A strategy, prioritising differentiated, patient-centric products over plain-vanilla brand acquisitions. Internal capital expenditure and R&D investments remain elevated to support long-term growth. From a risk perspective, potential US tariffs are not expected to materially impact generics, though branded products may face greater pressure. Regulatory scrutiny remains a key risk, particularly in manufacturing compliance. Cipla eyes Day 1 launch of GLP-1 drug in 2026 Cipla has identified the GLP-1 category—led by blockbuster drug Semaglutide—as its most significant therapeutic opportunity in the next five years. The company aims for a Day 1 launch after patents expire in mid-2026, using a mix of in-house and partner filings in key global markets. Calling the GLP-1 space 'transformational,' Cipla is adopting a dual filing strategy through both in-house development and external partnerships to ensure early market entry. 'We see the GLP-1 category, including Semaglutide, as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, Managing Director and Global CEO of Cipla. 'Our approach is a mix of own and partner filings to ensure market presence from day one, especially in key markets.' In India, Cipla is working on an economically viable strategy not only for Semaglutide but for the entire GLP-1 portfolio, anticipating price erosion post-2026 but offset by volume growth. Cipla is also monitoring a recent Delhi High Court order restricting fixed-dose GLP-1 combinations but does not anticipate major disruptions for mono-variant GLP-1 therapies. Earlier, Dr. Reddy's Laboratories revealed plans to enter the GLP-1 space with Semaglutide across 87 countries starting in 2026.
&w=3840&q=100)
First Post
25 minutes ago
- First Post
India extends ₹4,850 crore line of credit to Maldives during PM Modi's visit, FTA talks begin
India has extended a new line of credit worth ₹4,850 crore to the Maldives, Foreign Secretary Vikram Misri announced during Prime Minister Narendra Modi's state visit to Malé read more India has extended a fresh line of credit worth ₹4,850 crore to the Maldives, Foreign Secretary Vikram Misri said on Friday. The announcement was made during Prime Minister Narendra Modi's state visit to Malé. #WATCH | Malé, Maldives | On PM Modi's visit to Maldives, Foreign Secretary Vikram Misri says, "We have signed an MoU related to the extension of a fresh line of credit, of Rs 4850 crore to the Maldives. This is the first Line of Credit (LoC) extended to the Maldives that is… — ANI (@ANI) July 25, 2025 STORY CONTINUES BELOW THIS AD 'This Line of Credit represents a continuation of the tradition of assistance to the development needs of the Maldives,' Misri said, adding that the funds are expected to support a range of infrastructure projects that will benefit the Maldivian people. In addition to the new credit line, the two sides also signed a mandatory agreement amending an existing dollar-denominated line of credit. The revision is set to significantly ease the Maldives' debt burden, slashing its annual repayment obligations by 40 per cent from nearly $51 million to $29 million. The credit extension and debt restructuring come amid efforts by both countries to strengthen bilateral ties with PM Modi's visit being the first by a foreign head of state or government during President Muizzu's term. PM Modi also announced that discussions for the free trade agreement have also started between the two nations.
